GLPwatch
Papers (10378)
Page 103 of 173, ranked by citation count.
- Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.
- Anti-obesity drug also protects against heart disease - what happens next?
- Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.
- Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice.
- Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.
- Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
- Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant only.
- Semaglutide, a newly available glucagon-like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes.
- A peripherally restricted cannabinoid-1 receptor inverse agonist promotes insulin secretion and protects from cytokine toxicity in human pancreatic islets.
- Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis.
- Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a case report.
- Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.
- Pharmacologic stimulation of central GLP-1 receptors has opposite effects on the alterations of plasma FGF21 levels induced by feeding and fasting.
- Self-Assembly of Exendin-4-Derived Dual Peptide Agonists is Mediated by Acylation and Correlated to the Length of Conjugated Fatty Acyl Chains.
- The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.
- Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
- A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.
- The GLP-1 analog exendin-4 modulates HSP72 expression and ERK1/2 activity in BTC6 mouse pancreatic cells.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes.
- Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.
- Pharmacological treatment of non-responders following bariatric surgery.
- Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study.
- Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.
- Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans.
- G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.
- Tirzepatide: a new low for bodyweight and blood glucose.
- Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis.
- Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.
- Add-on value of tirzepatide versus semaglutide.
- Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography-tandem mass spectrometry method and its application.
- Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.
- Pancreatitis associated with incretin-based therapies.
- Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression.
- GLP-1 agonist associated acute kidney injury: A case report and review.
- An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption.
- Liraglutide for type 2 diabetes mellitus.
- Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report.
- Remission of insulin resistance in type 2 diabetic patients after gastric bypass surgery or exenatide therapy.
- Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
- [Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control].
- A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists.
- The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats.
- Long-acting PYY<sub>3</sub> <sub>-36</sub> analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.
- Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
- Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy to Liraglutide, a Human Glucagon-like Peptide-1 Analog--Results from a Pilot Study in Japan-.
- Preparation of [<sup>177</sup>Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies.
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.
- Albiglutide for the treatment of type 2 diabetes.
- Exendin-4 improves ER stress-induced lipid accumulation and regulates lipin-1 signaling in HepG2 cells.
- Alleviation of hyperglycemia induced vascular endothelial injury by exenatide might be related to the reduction of nitrooxidative stress.
- Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
- Tirzepatide and the new era of twincretins for diabetes.
- Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study.
- Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
- GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin.
- The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials.
- Semaglutide-associated hyposalivation: A report of case series.
- Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
- Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.